HC Wainwright Has Optimistic Outlook of RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright increased their Q1 2025 EPS estimates for Arcus Biosciences in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.12) per share for the quarter, up from their previous forecast of ($1.30). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($4.50) EPS, FY2027 earnings at ($4.67) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($1.96) EPS.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $36.00 million for the quarter, compared to analysts’ expectations of $29.38 million.

Several other analysts also recently weighed in on the stock. Bank of America cut their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Morgan Stanley decreased their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $30.25.

Arcus Biosciences Trading Down 2.7 %

NYSE:RCUS opened at $9.87 on Friday. Arcus Biosciences has a 12-month low of $9.85 and a 12-month high of $20.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The business has a 50 day simple moving average of $13.46 and a 200 day simple moving average of $15.42. The firm has a market capitalization of $1.04 billion, a P/E ratio of -3.13 and a beta of 0.84.

Institutional Trading of Arcus Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after purchasing an additional 833 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcus Biosciences by 2.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock valued at $471,000 after buying an additional 843 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Arcus Biosciences by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after buying an additional 1,117 shares during the last quarter. R Squared Ltd bought a new position in Arcus Biosciences during the fourth quarter valued at approximately $26,000. Finally, Teacher Retirement System of Texas lifted its stake in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after acquiring an additional 2,410 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Arcus Biosciences

In related news, CEO Terry J. Rosen bought 19,800 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 12.30% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.